Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Tina Vilsbøll; Birgitte Brock; Hans Perrild; K Levin; Hans-Henrik Lervang; Klaus Erik Kølendorf; T Krarup; Ole Schmitz; M Zdravkovic; Xuan Le Thi Thanh; S Madsbad

doi:http://dx.doi.org/10.1111/j.1464-5491.2007.02333.x

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Tina Vilsbøll, Birgitte Brock, Hans Perrild, K Levin, Hans-Henrik Lervang, Klaus Erik Kølendorf, T Krarup, Ole Schmitz, M Zdravkovic, Xuan Le Thi Thanh, S Madsbad

Department of Clinical Medicine

190 Citations (Scopus)

Abstract

To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.

Original language	English
Journal	Diabetic Medicine
Volume	25
Issue number	2
Pages (from-to)	152-6
Number of pages	5
ISSN	0742-3071
DOIs	https://doi.org/10.1111/j.1464-5491.2007.02333.x
Publication status	Published - 1 Feb 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://dx.doi.org/10.1111/j.1464-5491.2007.02333.x

Cite this

Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H-H., Kølendorf, K. E., Krarup, T., Schmitz, O., Zdravkovic, M., Le Thi Thanh, X., & Madsbad, S. (2008). Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabetic Medicine, 25(2), 152-6. https://doi.org/10.1111/j.1464-5491.2007.02333.x

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. / Vilsbøll, Tina; Brock, Birgitte; Perrild, Hans et al.

In: Diabetic Medicine, Vol. 25, No. 2, 01.02.2008, p. 152-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Vilsbøll, T, Brock, B, Perrild, H, Levin, K, Lervang, H-H, Kølendorf, KE, Krarup, T, Schmitz, O, Zdravkovic, M, Le Thi Thanh, X & Madsbad, S 2008, 'Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus', Diabetic Medicine, vol. 25, no. 2, pp. 152-6. https://doi.org/10.1111/j.1464-5491.2007.02333.x

@article{3ea0c686e19e474cacaecb505fb53bee,

title = "Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus",

abstract = "To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.",

author = "Tina Vilsb{\o}ll and Birgitte Brock and Hans Perrild and K Levin and Hans-Henrik Lervang and K{\o}lendorf, {Klaus Erik} and T Krarup and Ole Schmitz and M Zdravkovic and {Le Thi Thanh}, Xuan and S Madsbad",

year = "2008",

month = feb,

day = "1",

doi = "http://dx.doi.org/10.1111/j.1464-5491.2007.02333.x",

language = "English",

volume = "25",

pages = "152--6",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

AU - Vilsbøll, Tina

AU - Brock, Birgitte

AU - Perrild, Hans

AU - Levin, K

AU - Lervang, Hans-Henrik

AU - Kølendorf, Klaus Erik

AU - Krarup, T

AU - Schmitz, Ole

AU - Zdravkovic, M

AU - Le Thi Thanh, Xuan

AU - Madsbad, S

PY - 2008/2/1

Y1 - 2008/2/1

N2 - To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.

AB - To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase insulin release were measured by means of the insulin-modified frequently sampled intravenous glucose tolerance test. Arginine-stimulated insulin secretion was measured during a hyperglycaemic clamp (20 mmol/l). Glucose effectiveness and insulin sensitivity were estimated by means of the insulin-modified frequently sampled intravenous glucose tolerance test.

U2 - http://dx.doi.org/10.1111/j.1464-5491.2007.02333.x

DO - http://dx.doi.org/10.1111/j.1464-5491.2007.02333.x

M3 - Journal article

SN - 0742-3071

VL - 25

SP - 152

EP - 156

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 2

ER -

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this